Noticias de PYXS_US

Noticias del mercado

Últimas noticias sobre PYXS_US — 143 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PYXS_US ✕ 143 resultados
25/04/2026 PYXS_US — Quartr
Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025 Summary

Resumen de Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025, que combina transcripciones, diapositivas y documentos relacionados.

23/04/2026 PYXS_US — MSN
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94
18/04/2026 PYXS_US — Investing.com
Pyxis presents preclinical data on MICVO in head and neck cancer
18/04/2026 PYXS_US — The Manila Times
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
18/04/2026 PYXS_US — Investing.com
Pyxis presents preclinical data on MICVO in head and neck cancer
17/04/2026 PYXS_US — Investing.com
Pyxis presents preclinical data on MICVO in head and neck cancer By Investing.com
17/04/2026 PYXS_US — Investing.com
Pyxis presents preclinical data on MICVO in head and neck cancer
17/04/2026 PYXS_US — GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Showing
17/04/2026 PYXS_US — Stock Titan
Pyxis AACR data: MICVO combo beat either treatment alone
17/04/2026 PYXS_US — GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Showing
17/04/2026 PYXS_US — Investing.com
Pyxis presents preclinical data on MICVO in head and neck cancer
17/04/2026 PYXS_US — Investing.com
Pyxis presents preclinical data on MICVO in head and neck cancer
17/04/2026 PYXS_US — Yahoo Finance
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
12/04/2026 PYXS_US — Quiver Quantitative
PYXS | Pyxis Oncology, Inc. Common Insider Trading
12/04/2026 PYXS_US — MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages
07/04/2026 PYXS_US — The Legal Advocate
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69% - Cash Flow Strong Stocks
07/04/2026 PYXS_US — The Legal Advocate
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69% - High Beta Stocks
07/04/2026 PYXS_US — tayninh.gov.vn
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69% - IPO Watch
07/04/2026 PYXS_US — Newser
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69% - Hot Momentum Watchlist
07/04/2026 PYXS_US — laocai.gov.vn
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69% - Stock Community Signals

Página 5 de 8

keyboard_arrow_up